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ABSTRACT
Cytomegalovirus (CMV) infection is of great importance to obstetrician-gynecologists because
maternal infection is relatively common and can result in severe injury to the fetus. The greatest risk
to the fetus occurs when the mother develops a primaryCMV infection in the first trimester. Forty
to 50% of infants delivered to mothers with primaryCMV infections will have congenital infections.
Of these neonates, 5-18% will be overtly symptomatic at birth. Approximately 30% of severely
infected infants die, and 80% have severe neurologic morbidity. Eighty-five to 90% of infants will be
asymptomatic, and 10-15% of these babies subsequently have sequelae such as visual and auditory
defects. If the mother develops a recurrent or reactivatedCMV infection during pregnancy, the risk
of a severe congenital infection is very low. Perinatal infection, as opposed to congenital infection,
may result from exposure to the virus during delivery or lactation and rarely leads to serious
sequelae. Antimicrobial therapy and immunotherapy for CMV are, at present, unsatisfactory.
Therefore, all patients, pregnant women in particular, must be educated about preventive mea-
sures. (C) 1994 Wiley-Liss, Inc.
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Ytomegalovirus (CMV) infection is of great
importance to obstetrician-gynecologists for
several reasons. First, although CMV typically
causes either asymptomatic or mildly symptomatic
illness in children and adults, it can cause devastat-
ing systemic infections in irnmunocompromised pa-
tients, particularly individuals who have received
organ transplants or who have human immunodefi-
ciency virus (HIV) infections. Second, the virus
can disseminate across the placenta and infect the
fetus, even in a woman with a high serum concen-
tration of viral-specific antibody. Third, an assess-
ment of the empiric risk to the fetus can be difficult
in any specific patient. Fourth, no consistently ef-
fective form of immunotherapy or chemotherapy is
available; therefore, physicians must be constantly
attuned to the issue of disease prevention.
This article initially reviews the virology and
epidemiology of CMV infection. Special emphasis
is placed on the accurate classification of maternal,
fetal, and neonatal infections. Subsequently, the
text considers the prognosis in infected infants and
examines several techniques for the prenatal diag-
nosis of CMV infection. Finally, consideration is
given to measures of proven value in reducing the
risk of acquiring CMV infection.
EPIDEMIOLOGY
CMV is a double-stranded DNA virus that repli-
cates within the nucleus of an infected cell. Hu-
mans are the only known host for this virus. Like
herpes simplex virus, CMV may remain latent in
host cells after the initial infection. Recurrent in-
fection is usually due to the reactivation of endoge-
nous latent virus rather than reinfection with a new
strain of virus. Cell-mediated immunity is more
important than humoral mechanisms in controlling
infection.
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CMV is not highly contagious, and close per-
sonal contact is required for infection to occur.
Horizontal transmission may result from the receipt
of an infected organ or blood, from sexual contact,
or from contact with contaminated saliva or urine.
Vertical transmission may occur as a result of trans-
placental infection, exposure to contaminated geni-
tal-tract secretions during delivery, or breast-feed-
ing. The incubation period of the virus ranges
from 28 to 60 days, with a mean of 40 days.
1-3
Among young children, the most important risk
factor for infection is close contact with playmates,
particularly in the setting of day care. In an early
report, Pass and coworkers
4 surveyed 70 children
attending a day-care center in Birmingham, AL.
Investigators obtained mouth swabs from 29 chil-
dren and urine specimens from 68. Forty-five per-
cent of the mouth swabs and 53% of the urine
cultures were positive for CMV. Nine percent of
infants younger than year of age shed the virus in
either saliva or urine; 83% of children 1-2 years of
age shed the virus.
Jones et al. s conducted a similar survey in a
regular day-care center and a facility for develop-
mentally delayed children. Twenty-two percent of
the children in both centers were viruric, and 11%
shed CMV in their saliva. Hutto and coworkers
6
surveyed 47 toddlers attending day care. Fourteen
(30%) shed the virus in saliva. The highest rate of
salivary excretion (80%) occurred in children
12-24 months of age. Forty percent of the children
were viruric. Interestingly, CMV was recovered
from 2/70 toy surfaces that were randomly selected
for culture. However, the virus was isolated from
5/7 toys immediately after removal from the mouth
of a child known to be shedding CMV in saliva.
After 10 and 30 min, 4 and 2 toy surfaces, respec-
tively, were still positive.
Infected children clearly pose a risk of transmit-
ting the virus to adult day-care workers. Adler
7
recently examined the risk of seroconversion to
CMV among day-care employees. At the time of
the initial assessment, 202 workers were seronega-
tive. Within 10 months, 19 (11%) had serocon-
vetted. The risk of seroconversion was greatest
among employees who cared for children under 2
years of age.
Small children also pose a risk to members of
their own families. Taber et al. performed a sero-
logic study and identified 68 families in which both
parents were seronegative for CMV. Over a 3-year
period, seroconversion occurred in or more mem-
bers of 37 families (53%). The mean annual sero-
conversion rates were approximately 10% for fa-
thers, mothers, and children. The index case was
usually a child.
In addition to acquiring infection from young
children, adolescents and adults may develop infec-
tion as a result of sexual contact. CMV infection is
endemic among gay men and heterosexuals with
multiple partners.
1,9 Additional risk factors for in-
fection include lower socioeconomic status, history
of abnormal cervical cytology, birth outside of
North America, first pregnancy at younger than 15
years, and coinfection with other sexually transmit-
ted diseases (STDs) such as trichomoniasis.
10
CLINICAL MANIFESTATIONS IN CHILDREN
AND ADULTS
Most children who acquire CMV infection are as-
ymptomatic. When clinical manifestations are
present, they usually are mild and include malaise,
fever, lymphadenopathy, and hepatosplenomegaly.
Similarly, most adults with either primary or re-
current CMV infection are asymptomatic. Symp-
tomatic patients typically have findings suggestive
ofmononucleosis. Respiratory infection is distinctly
uncommon in adults with normal immune func-
tions. However, Lipton et al.
11 have reported a
case of fatal CMV pneumonitis in an ostensibly
healthy postpartum woman. Additional cases of se-
rious CMV infection are likely to occur as a conse-
quence of the increasing prevalence of HIV infec-
tion in women.
DIAGNOSIS OF INFECTION IN ADULTS
AND CHILDREN
The diagnosis ofCMV infection can be confirmed
by the isolation of the virus in tissue culture. The
highest concentrations ofCMV are usually present
in urine and seminal fluid, followed by saliva and
breast milk. Several different cell lines have been
used to support viral growth, and techniques such
as the viral shell assay, immunofluorescent stain-
ing, monoclonal antibody, and polymerase chain
reaction (PCR) permit the identification of viral
antigen within 24 h.
12-15
Serologic methods also are helpful in establish-
ing the diagnosis of CMV infection provided that
the reference laboratory is skilled in performing
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such tests. In the acute phase of infection, viral-
specific IgM antibody is present in serum. IgM
titers decline rapidly over a period of 30-60 days.
There is no absolute IgG titer that clearly will
differentiate acute from recurrent infection. How-
ever, a 4-fold or greater change in the IgG titer is
consistent with recent acute infection. Other labo-
ratory tests suggestive ofCMV infection include a
differential white blood cell (WBC) count showing
atypical lymphocytes, a low platelet count and ele-
vated serum transaminase concentrations.
CONGENITAL AND PERINATAL
INFECTION
As a result of exposure to either young children or
infected sexual partners, approximately 50-80% of
adult women in the United States have serologic
evidence of past CMV infection. Unfortunately,
the presence of antibody is not perfectly.protective
against vertical transmission; thus, pregnant women
with recurrent or primary infection pose special
risks to their fetuses.
Fetal and neonatal CMV infections may occur at
3 distinct times: antepartum, intrapartum, and post-
partum. Antepartum or congenital infection is the
greatest risk to the fetus and is perhaps the most
difficult to understand because of the often dispar-
ate statistics reported in epidemiologic surveys.
Congenital (Antepartum)Infection
Congenital CMV infection results from hematoge-
nous dissemination of the virus across the placenta.
Dissemination may occur with primary or recur-
rent (reactived) infection but is much more likely
to occur in the former setting. From to 4% of
16 uninfected women seroconvert during pregnancy.
In women who acquire primary infection, 40-50%
ofthe fetuses will be infected. Based on work with a
guinea-pig model, Kumar and Prokay
17 have con-
cluded that the overall risk of congenital infection
is greatest when a maternal infection occurs in the
third trimester, but the probability of severe fetal
injury is highest when a maternal infection occurs
in the first trimester.
Of fetuses with congenital infection, 5-18% will
be overtly symptomatic at birth. The most common
clinical manifestations and laboratory abnormalities
in these infants are listed in Table 1. Approxi-
mately 30% of severely infected infants die. Eighty
percent of the survivors have severe neurologic
TABLE I. Common clinical findings and laboratory
abnormalities in congenital CMV infection
Physical findings and
laboratory abnormalities
Approximate
frequency (%)
Physical findings
Enlargement of liver and/or spleen 52
Petechiae 5
Intracranial calcifications 43
Jaundice 38
Growth restriction 38
Microcephaly 27
Chorioretinitis 15
Sensorineural hearing loss 15
Mental retardation 13
Seizures 10
Laboratory abnormalities
Thrombocytopenia 52
Hyperbilirubinemia 35
Increased alanine aminotransferase 26
alnformation in this table is based upon data presented in references 18
and 19.
20-50% of pregnant susceptible
1-4% seroconve during pregnancy
40-5nfted
5-15%syp ptomatic
at birth at birth
Up to 30% die 80% of survivors 10-15% subsequently
have serious develop neurologic,
sequelae auditory, ocular,
dental defects
Fig. I. Frequency and severity of congenital CMV infection
following primary maternal infection.
morbidity, ocular abnormalities, or sensorineural
hearing loss. 8’ 19 Approximately 85-90% of in-
fants delivered to mothers with primary infection
will be asymptomatic at birth. Ten to 15% subse-
quently develop hearing loss, chorioretinitis, or
dental defects within the first 2 years of life. The
outcomes of neonates exposed to primary maternal
CMV infection are summarized in Figure 1.
Pregnant women who experience recurrent
CMV infection are much less likely to transmit
infection to their fetuses. Recurrent infection oc-
curs predominantly as a result of reactivation of a
latent infection rather than reinfection with a new
viral strain. The most recent, and probably clear-
est, delineation of fetal risk in this situation is the
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report by Fowler et al.
19 In an excellent epidemio-
logic investigation, these authors studied 125
women with serologic evidence of primary infec-
tion and 64 with recurrent infection. In the former
group, 18% of infants were symptomatic at birth.
An additional 7% (total 25%) developed at least
major sequela within 5 years of follow-up. Two
percent died, 15% had sensorineural hearing loss,
and 13% had IQs lower than 70. In contrast, none
of the infants delivered to mothers with recurrent
infection were symptomatic at birth. During the
period of surveillance, 8% had at least sequela,
but none had multiple defects. The most common
sequela was hearing loss. The authors concluded
that maternal antibody provided substantial, but
not complete, protection against serious fetal inec-
tion.
Overall, approximately 40,000 (1%) infants
born in the United States each year have congenital
CMV infection. Approximately 3,000-4,000 in-
fants are symptomatic at birth, and an additional
4,000-6,000 subsequently have neurologic or de-
velopmental problems in the first years of life.
CMV infection is now the principal cause of hear-
ing deficits in children. Public-health officials esti-
mate that the annual cost of caring for children with
congenital CMV is $1.86 billion,z
Perinatal (Intrapartum and Postpartum)
Infection
Perinatal infection may occur during delivery as a
result of exposure to infected genital-tract secre-
tions. At the time of delivery, up to 10% of preg-
nant women may be shedding CMV in cervical
secretions and/or urine. Twenty to 60% of exposed
fetuses may subsequently shed CMV in their phar-
ynx and/or urine. The incubation period for this
form of infection ranges from 7 to 12 weeks, with
an average of 8 weeks. Fortunately, infected infants
rarely have serious sequelae from infection acquired
during delivery.
18,21
Perinatal infection also may develop as a result of
breast-feeding. Stagno et al.
2z surveyed 278 women
who had recently delivered and who agreed to pro-
vide samples of breast milk. Thirty-eight (13%)
had CMV isolated at least once from colostrum or
milk. Twenty-eight of these women were shedding
CMV only in breast milk. Nineteen of their neo-
nates were breast-fed, and 11 (58%) acquiredCMV
infection despite the presence of neutralizing anti-
body in breast milk. Fortunately, serious sequelae
did not occur in infected infants.
DIAGNOSIS OF CONGENITAL INFECTION
Several techniques are now available to evaluate the
fetus with suspected congenital CMV infection.
Katz et al.
23 were the first to report the association
between elevated second-trimester maternal serum
alpha-fetoprotein (MSAFP) and congenital infec-
tion. They were not able to define the precise expla-
nation for elevation in MSAFP. In view of the
nonspecific nature of this test and the multiple other
causes for elevated concentrations of this protein,
MSAFP screening should not be considered a use-
ful test for the diagnosis of congenital CMV infec-
tion.
Much attention in recent years has focused on
the analysis of amniotic fluid (AF) and fetal serum
as a means to diagnose congenital infection. Several
authors have compared the relative value of the
following diagnostic tests: viral culture of AF and
fetal serum, determination of total IgM concentra-
tion in fetal serum, identification ofanti-CMV IgM
in fetal serum, and assessment of fetal liver-func-
tion tests. These reports uniformly have supported
the superiority of AF culture in confirming the
diagnosis of congenital CMV infection.
Lange and coworkers
24 were the first to report
the successful diagnosis of congenital infection by
assessment of fetal blood. They performed cordo-
centesis on a hydropic fetus at 25 week gestation.
The fetal blood smear showed severe erythroblasto-
sis. Total IgM concentration was normal, but vi-
ral-specific IgM antibody to CMV was detected by
radioimmunoassay.
Hohlfeld et al.
2 subsequently described their
assessment of 15 women with documented primary
CMV infection in pregnancy. Eight fetuses were
infected. All were correctly identified by the detec-
tion of antigen in AF by the shell-viral assay. In
each instance, the subsequent viral culture was pos-
itive. Only 4 fetuses (50%) had increased total
IgM concentrations and abnormal liver-function
tests. Two fetuses had thrombocytopenia, and none
had positive viral blood cultures. The finding of a
negative AF culture was 100% specific in predict-
ing the absence of congenital infection.
Lynch and coauthors
4 recently described their
experience with the assessment of 12 patients, 7 of
whom had serologically confirmed primary infec-
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tion and 5 of whom were evaluated because of
abnormal sonographic findings. Eleven of the pa-
tients had amniocenteses and cordocenteses. Of" the
7 women with primary CMV infection, only had
a confirmed fetal infection. This fetus had a normal
hematocrit and platelet count, negative IgM-spe-
cifi antibody, an elevated gamma-glutamyl-
transpeptidase (GGTP) concentration, and a posi-
tive AF culture. In the group of 5 women with
abnormal sonograms, all of the fetuses were in-
fected. Four fetuses (80%) had positive AF cul-
tures, and none had a positive blood culture. One
had thrombocytopenia, 3 had elevated GGTP con-
centrations, and 4 had elevated total IgMs.
Lamy et al.
3 reported a large survey of 861
pregnant women who initially were seronegative
for CMV. Seroconversion occurred in 20 (2.3%)
during pregnancy. Seven of these women agreed to
have invasive diagnostic testing. Five of 7 AF cul-
tures were positive; only 3 fetuses had IgM-specific
antibody.
In the most recent and largest series of invasive
diagnostic testing for congenital CMV infection,
Donner et al. s assessed 52 fetuses at risk for con-
genital CMV infection. Sixteen fetuses were in-
fected, 13 of whom were diagnosed antenatally.
Thirteen of 16 (81%) had at least abnormal test.
The detection of virus in AF by culture or PCR
methodology correctly identified 12 (75%) infected
fetuses. Four patients required 2 amniocenteses to
establish the diagnosis. Nine of 16 (56%) fetuses
had viral-specific IgM antibody in cord blood. Six
of 11 (55%) fetuses who had hematologic assays
were thrombocytopenic. A negative AF culture was
100% specific in identifying an unifected fetus.
Although identification of CMV in AF appears
to be the most sensitive and specific test for diag-
nosing congenital infection, it does not necessarily
identify the severity of fetal injury. This issue is
obviously ofgreat importance in counseling parents
about the prognosis for their infant. Fortunately,
detailed sonography can be invaluable in providing
information about the severity of fetal impairment.
The principal sonographic findings suggestive of
serious fetal injury include microcephaly, ventricu-
lomegaly, intracerebral calcifications, hydrops,
growth restriction, and oligohydramnios.
2s In ad-
dition, unusual findings that may also indicate a
severely infected infant include fetal heart
block, 26’27 intraabdominal echodensities,
2 meco-
nium peritonitis,
29 and isolated serous effusions.
2s
Clinicians should be aware that the ultrasound ex-
amination may be normal early in the course of fetal
infection. Therefore, fetuses at risk should have
repeat examinations to determine if anomalies are
apparent.
TREATMENT AND PREVENTION
At the present time, a vaccine for CMV is not
available. Antiviral agents such as ganciclovir and
foscarnet have moderate activity against CMV, but
their use is limited primarily to the treatment of
severe infections in immunocompromised patients.
Accordingly, obstetrician-gynecologists should fo-
cus most of their attention on educating patients
about preventive measures.
One of the most important interventions is help-
ing patients understand that CMV infection can be
an STD and that sexual promiscuity significantly
increases an individual’s risk ofacquiring the infec-
tion. Individuals who have multiple sexual part-
ners should be counseled that latex condoms pro-
vide an effective barrier to the transmission of
CMV. 29’30 Another important intervention is edu-
cating health-care workers, day-care workers, ele-
mentary-school teachers, and mothers ofyoung chil-
dren about the importance of simple infection
control measures such as handwashing and proper
cleansing of environmental surfaces. Obstetricians
and pediatricians must be consistently aware of the
importance of transfusing only CMV-free blood
products to fetuses, neonates, pregnant women, and
immunocompromised patients and of screening po-
tential donors of organs and semen for CMV infec-
tion.
2 Finally, health-care workers must adhere to
the principles of universal precautions when treat-
ing patients and handling potentially infected body
fluids.
16
At the present time, there are several reasons
why routine prenatal screening for CMV infection
is not recommended. First, laboratory resources
may become overwhelmed if all pregnant women
are screened. Second, if laboratories do not insure a
high level of quality control, the interpretation of
serologic tests may be confusing and may lead to
incorrect, and irreversible, interventions such as
pregnancy termination. When evaluating test re-
sults, clinicians must be aware that IgM-specific
antibody may persist for up to 60 days after the
acute infection. Therefore, they must carefully as-
150 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYCMV INFECT10N IN PREGNANCY DUFF
sess the patient’s clinical history to determine the
most likely time of infection with respect to concep-
tion. Third, neither antiviral chemotherapy nor
immunoprophylaxis is available to protect the fetus
or neonate. Accordingly, screening should be lim-
ited to women who have symptoms suggestive of
acute CMV infection, who have had definite occu-
pational exposure to CMV, or who are immuno-
compromised.
CONCLUSIONS
CMV infection is the most common congenital in-
fection in the United States, affecting approximately
1% of all neonates. The most serious fetal injuries
result from primary maternal infection. Mothers
with recurrent infections are much less likely to
transmit infection to their fetuses. The most valu-
able tests for confirming the diagnosis of congenital
CMV infection and determining the severity of
fetal injury are culture ofAF and ultrasonography.
Infants also may acquire CMV infection as a result
of exposure to CMV during delivery or during
breast-feeding. Serious sequelae from this type of
infection are much less common than following
primary infection. Antimicrobial therapy and im-
munotherapy for CMV infection are, at present,
unsatisfactory. Therefore, patients must be edu-
cated to avoid high-risk behavior.
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